title: Bendamustine and rituximab combination in the management of chronic lymphocytic leukemia-associated autoimmune hemolytic anemia: a multicentric retrospective study of the French CLL intergroup (GCFLLC/MW and GOELAMS).
abstract: We report our experience on bendamustine and rituximab (BR) combination in 26 patients with chronic lymphocytic leukemia (CLL) complicated by autoimmune hemolytic anemia (AIHA). At the time of BR initiation, 88% of the patients had already been treated for AIHA and CLL was progressive regardless of AIHA in all patients but one. Overall response rates were 81% for AIHA and 77% for CLL. Median time to next treatment was 28.3 months and 26.2 months for AIHA and CLL, respectively. BR therapy may represent a good and safe therapeutic option in this setting where adequate control of CLL seems important for long-term AIHA response.
authors.affiliation: CHU Reims, Hôpital Robert Debré, Service d'Hématologie Clinique, Rue du général Koenig, Reims F-51092, France; Université Reims Champagne Ardenne, UFR Médecine, 51 rue Cognac Jay, Reims F-51095, France.
authors.forename: Anne
authors.initials: A
authors.lastname: Quinquenel
authors.forename: Christophe
authors.initials: C
authors.lastname: Willekens
authors.forename: Jehan
authors.initials: J
authors.lastname: Dupuis
authors.forename: Bruno
authors.initials: B
authors.lastname: Royer
authors.forename: Loic
authors.initials: L
authors.lastname: Ysebaert
authors.forename: S
authors.initials: S
authors.lastname: De Guibert
authors.forename: Anne-Sophie
authors.initials: AS
authors.lastname: Michallet
authors.forename: Pierre
authors.initials: P
authors.lastname: Feugier
authors.forename: Romain
authors.initials: R
authors.lastname: Guieze
authors.forename: Vincent
authors.initials: V
authors.lastname: Levy
authors.forename: Alain
authors.initials: A
authors.lastname: Delmer
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000744:Anemia, Hemolytic, Autoimmune / Q000150:complications / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000069461:Bendamustine Hydrochloride; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000150:complications / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use*; D012189:Retrospective Studies; D000069283:Rituximab; D016019:Survival Analysis
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D000970:Antineoplastic Agents; D009588:Nitrogen Mustard Compounds; D000069283:Rituximab; D000069461:Bendamustine Hydrochloride